Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19685915 | 0.96 | BRD4 (0.32) | BRD4KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL19685724 | 0.90 | PKM (0.33) | BRD4PKMTDP1 | |
| SCHEMBL19686025 | 0.90 | BRD4 (0.33) | BRD4 | |
| SCHEMBL19685831 | 0.89 | LMNA (0.34) | KDM4EALDH1A1LMNAMAPTG6PD | |
| SCHEMBL19686083 | 0.86 | POLB (0.34) | BRD4MAPTPKMTDP1 | |
| SCHEMBL19686082 | 0.86 | BRD4 (0.35) | BRD4 | |
| SCHEMBL19685917 | 0.86 | ATM (0.34) | NR3C2 | |
| SCHEMBL19685822 | 0.86 | GSK3B (0.34) | KDM4EALDH1A1RAB9ANR3C2 | |
| SCHEMBL19685879 | 0.85 | LMNA (0.36) | KDM4EALDH1A1LMNAMAPTG6PD | |
| SCHEMBL19685854 | 0.83 | PGR (0.32) | KDM4EALDH1A1LMNAMAPTG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | CYC1, CCNA1, CYCS | BRD4 740/4885KDM4E 1138/4885ALDH1A1 572/4885 |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | CYC1, CCNA1, CYCS | BRD4 740/4885KDM4E 1138/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.